Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;2(1):27-38.
doi: 10.1177/2042018810391900.

Clinical Approach to the Treatment of Painful Diabetic Neuropathy

Affiliations

Clinical Approach to the Treatment of Painful Diabetic Neuropathy

Alexandra Hovaguimian et al. Ther Adv Endocrinol Metab. 2011 Feb.

Abstract

Painful neuropathy is a common and often progressive complication of diabetes. Patients frequently report symptoms of tingling, burning, lancinating pain, hyperesthesia and allodynia. The natural history of the disease may vary from intermittent mild symptoms to severe chronic daily pain; the latter is often associated with diminished quality of life. There are a variety of pharmaceutical agents from different medicinal categories available for the symptomatic treatment of painful diabetic neuropathy, however selecting an agent is often challenging given the breadth of choices and lack of consistent guidelines. As a result, many patients remain untreated or undertreated.This article presents a practical clinical approach to the treatment of pain in diabetic neuropathy. Recommendations for first, second and third line medications are based on specific evidence for the treatment of painful diabetic neuropathy as well as safety, tolerability, drug interactions and cost. Additional topics of discussion include breakthrough pain, opioid use and topical therapies. This review does not comprehensively discuss all possible treatments for painful neuropathy, but provides a systematic approach designed to guide clinicians in tailoring therapies to the individual patient.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Similar articles

Cited by

References

    1. Agrawal R.P., Goswami J., Jain S., Kochar D.K. (2009) Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract 83: 371–378 - PubMed
    1. Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J., et al. (2003) The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. Diabetes Care 26: 770–776 - PubMed
    1. Arezzo J.C., Rosenstock J., LaMoreaux L., Pauer L. (2008) Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial. BMC Neurol 8: 33. - PMC - PubMed
    1. Argoff C.E., Cole B.E., Fishbain D.A., Irving G.A. (2006) Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin Proc 81: S3–S11 - PubMed
    1. Argoff C.E., Galer B.S., Jensen M.P., Oleka N., Gammaitoni A.R. (2004) Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the Neuropathic Pain Scale. Curr Med Res Opin 20(Suppl. 2): S21–S28 - PubMed